248 related articles for article (PubMed ID: 28779637)
41. Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake.
Stecová J; Mehnert W; Blaschke T; Kleuser B; Sivaramakrishnan R; Zouboulis CC; Seltmann H; Korting HC; Kramer KD; Schäfer-Korting M
Pharm Res; 2007 May; 24(5):991-1000. PubMed ID: 17372681
[TBL] [Abstract][Full Text] [Related]
42. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC).
Fang JY; Fang CL; Liu CH; Su YH
Eur J Pharm Biopharm; 2008 Oct; 70(2):633-40. PubMed ID: 18577447
[TBL] [Abstract][Full Text] [Related]
43. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes.
Dubey V; Mishra D; Dutta T; Nahar M; Saraf DK; Jain NK
J Control Release; 2007 Nov; 123(2):148-54. PubMed ID: 17884226
[TBL] [Abstract][Full Text] [Related]
44. Cutaneous penetration of soft nanoparticles via photodamaged skin: Lipid-based and polymer-based nanocarriers for drug delivery.
Hung CF; Chen WY; Hsu CY; Aljuffali IA; Shih HC; Fang JY
Eur J Pharm Biopharm; 2015 Aug; 94():94-105. PubMed ID: 25986584
[TBL] [Abstract][Full Text] [Related]
45. Percutaneous permeation of betamethasone 17-valerate incorporated in lipid nanoparticles.
Zhang J; Smith E
J Pharm Sci; 2011 Mar; 100(3):896-903. PubMed ID: 20839362
[TBL] [Abstract][Full Text] [Related]
46. Histopathological evaluation of caffeine-loaded solid lipid nanoparticles in efficient treatment of cellulite.
Hamishehkar H; Shokri J; Fallahi S; Jahangiri A; Ghanbarzadeh S; Kouhsoltani M
Drug Dev Ind Pharm; 2015; 41(10):1640-6. PubMed ID: 25382163
[TBL] [Abstract][Full Text] [Related]
47. Nanocarriers Mediated Topical Drug Delivery for Psoriasis Treatment.
Gungor S; Rezigue M
Curr Drug Metab; 2017; 18(5):454-468. PubMed ID: 28228078
[TBL] [Abstract][Full Text] [Related]
48. Lipid nanocarriers for dermal delivery of lutein: preparation, characterization, stability and performance.
Mitri K; Shegokar R; Gohla S; Anselmi C; Müller RH
Int J Pharm; 2011 Jul; 414(1-2):267-75. PubMed ID: 21596122
[TBL] [Abstract][Full Text] [Related]
49. Topical drug delivery by a polymeric nanosphere gel: Formulation optimization and in vitro and in vivo skin distribution studies.
Batheja P; Sheihet L; Kohn J; Singer AJ; Michniak-Kohn B
J Control Release; 2011 Jan; 149(2):159-67. PubMed ID: 20950659
[TBL] [Abstract][Full Text] [Related]
50. Lipid nanoparticles for the topical delivery of retinoids and derivatives.
Morales JO; Valdés K; Morales J; Oyarzun-Ampuero F
Nanomedicine (Lond); 2015 Jan; 10(2):253-69. PubMed ID: 25600970
[TBL] [Abstract][Full Text] [Related]
51. Design of solid lipid nanoparticles for caffeine topical administration.
Puglia C; Offerta A; Tirendi GG; Tarico MS; Curreri S; Bonina F; Perrotta RE
Drug Deliv; 2016; 23(1):36-40. PubMed ID: 24735249
[TBL] [Abstract][Full Text] [Related]
52. Galactosyl Pentadecene Reversibly Enhances Transdermal and Topical Drug Delivery.
Kopečná M; Macháček M; Prchalová E; Štěpánek P; Drašar P; Kotora M; Vávrová K
Pharm Res; 2017 Oct; 34(10):2097-2108. PubMed ID: 28664316
[TBL] [Abstract][Full Text] [Related]
53. Increased therapeutic efficacy of a newly synthesized tyrosinase inhibitor by solid lipid nanoparticles in the topical treatment of hyperpigmentation.
Al-Amin M; Cao J; Naeem M; Banna H; Kim MS; Jung Y; Chung HY; Moon HR; Yoo JW
Drug Des Devel Ther; 2016; 10():3947-3957. PubMed ID: 27980392
[TBL] [Abstract][Full Text] [Related]
54. Microneedle and iontophoresis mediated delivery of methotrexate into and across healthy and psoriatic skin.
Vora D; Garimella HT; German CL; Banga AK
Int J Pharm; 2022 Apr; 618():121693. PubMed ID: 35331833
[TBL] [Abstract][Full Text] [Related]
55. An Innovative Approach in Nanotechnology-based Delivery System for the Effective Management of Psoriasis.
Parveen S; Ahmed M; Baboota S; Ali J
Curr Pharm Des; 2022; 28(13):1082-1102. PubMed ID: 35105284
[TBL] [Abstract][Full Text] [Related]
56. Nanostructured lipid carriers (NLCs) versus solid lipid nanoparticles (SLNs) for topical delivery of meloxicam.
Khalil RM; Abd-Elbary A; Kassem MA; Ghorab MM; Basha M
Pharm Dev Technol; 2014 May; 19(3):304-14. PubMed ID: 23528038
[TBL] [Abstract][Full Text] [Related]
57. Solid lipid nanoparticles as drug carriers for topical glucocorticoids.
Maia CS; Mehnert W; Schäfer-Korting M
Int J Pharm; 2000 Mar; 196(2):165-7. PubMed ID: 10699710
[TBL] [Abstract][Full Text] [Related]
58. Solid lipid microparticles for enhanced dermal delivery of tetracycline HCl.
Rahimpour Y; Javadzadeh Y; Hamishehkar H
Colloids Surf B Biointerfaces; 2016 Sep; 145():14-20. PubMed ID: 27131093
[TBL] [Abstract][Full Text] [Related]
59. Development and in vitro evaluation of lipid nanoparticle-based dressings for topical treatment of chronic wounds.
Gainza G; Chu WS; Guy RH; Pedraz JL; Hernandez RM; Delgado-Charro B; Igartua M
Int J Pharm; 2015 Jul; 490(1-2):404-11. PubMed ID: 26043822
[TBL] [Abstract][Full Text] [Related]
60. Polymeric nanoparticles modified with fatty acids encapsulating betamethasone for anti-inflammatory treatment.
Silva CO; Rijo P; Molpeceres J; Figueiredo IV; Ascensão L; Fernandes AS; Roberto A; Reis CP
Int J Pharm; 2015 Sep; 493(1-2):271-84. PubMed ID: 26222745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
